iiinova — where your digital self keeps evolving

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 24/09/2026

Our new review is published in Neuroscience & Biobehavioral Reviews! We analyzed global data on 35 neurological, mental, and substance use disorders. Together, these conditions account for 10 of the 25 leading causes of disability worldwide. doi.org/10.1016/j.ne...

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 19/05/2026

Thank you @apapsychiatric.bsky.social for highlighting our work in a press release at the APA Annual Meeting, and thank you @afspnational.bsky.social for supporting this research. Grateful to our Stanford team, especially co-first author Jason Tucciarone, mentor Alan Schatzberg, and collaborators

030 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 19/05/2026

Levels of depressive symptoms did not differ between groups, suggesting that the effect was specific to suicidal ideation rather than overall depression severity. These findings indicate that low-dose buprenorphine represents a promising treatment approach for #suicideprevention.

120 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 19/05/2026

50 participants with #depression and suicidal ideation received a single 0.5 mg/kg IV ketamine infusion over 40 min, followed by 4 weeks of low-dose buprenorphine (0.2–0.8 mg/day) or placebo. The buprenorphine group showed significantly greater reductions in suicidal ideation.

110 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 19/05/2026

New publication! 🧠 Excited to share our latest paper, for which I am co-first author. This randomized controlled trial provides the first evidence that #buprenorphine can prolong and augment #ketamine’s antisuicidal effects in #depression. doi.org/10.1176/appi...

230 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/05/2026

While the study remains preliminary and observational, the results contribute to the growing scientific discussion of psychedelic-assisted interventions and their potential effects on the brain.

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/05/2026

• Enlargement of multiple subcortical regions, including cerebellar, forebrain, and diencephalic structures • An average reduction of approximately 1.3 years in predicted brain age one month after treatment • Overall findings consistent with possible enhancement of structural neuroplasticity

100 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/05/2026

Using longitudinal MRI data from Special Operations veterans with blast-related traumatic brain injury, we observed structural brain changes following treatment with the magnesium-ibogaine (MISTIC) protocol, including: • Widespread increases in cortical thickness

110 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/05/2026

I’m very happy to share our new paper, recently published in iScience. Paper: doi.org/10.1016/j.is...

110 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/02/2026

Loved attending the Brazil Global Health Initiative event yesterday at Stanford. Always inspiring to connect with brilliant Brazilian researchers doing amazing work across Silicon Valley. Proud to be part of this community! 🇧🇷

020 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 21/01/2026

I had the privilege of sharing the stage with Drs. J. John Mann (Columbia), my incredible mentor, Alan Schatzberg (Stanford), Mina Rizk (Mount Sinai), and Yunyu Xiao (Cornell) for a thoughtful exchange on innovative approaches to suicide prevention.

000 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 21/01/2026

What an experience at #ACNP2026! Honored to present our Stanford randomized clinical trial demonstrating a novel strategy to sustain the antisuicidal effects of #ketamine in #depression as part of our mini-panel on buprenorphine and suicidality. @acnporg.bsky.social

131 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/01/2026

Grateful to be back at #ACNP2026, supported by my Past Travel Awardee Funding! I'm a Stanford postdoc leading trials in interventional psychiatry with #BrainStimulation and #Ketamine for depression and suicide prevention. Join our mini-panel on 01/13 and poster on 01/15! @acnporg.bsky.social

021 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 14/11/2025

Check out our new commentary in the International Journal of Neuropsychopharmacology (@ijnp.bsky.social) on ketamine–naltrexone clinical trial design for depression. doi.org/10.1093/ijnp...

030 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/08/2025

Privileged our mini-panel was selected for #ACNP2026 @acnporg.bsky.social. Grateful to join Drs. J. John Mann (‪Columbia‬), Alan Schatzberg (Stanford), Mina Rizk (Mount Sinai) and Yunyu Xiao (Cornell). Looking forward to the discussions ahead!

050 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/08/2025

Proud to receive the American College of Neuropsychopharmacology (ACNP) Past Travel Awardee Funding, recognizing my ongoing research progress. #ACNP2025 @acnporg.bsky.social

020 0

Reposted by Igor D. Bandeira, MD, PhD

NIHR Biomedical Research Centre: Maudsley @nihrmaudsleybrc.bsky.social · 24/07/2025

Research which is investigating why ketamine could be a good treatment for some people with depression, has discovered that the drug’s antidepressant effects involve the brain’s opioid system. The study was supported by @nihr.bsky.social and the MRC. www.maudsleybrc.nihr.ac.uk/posts/2025/j...

Dr Luke Jelen, lead author of the study and a Clinical Lecturer in Psychiatry at IoPPN King’s College London, said:

“Ketamine often makes the news for negative reasons. However, at a low dose, ketamine shows enormous potential to offer relief from the symptoms of depression.”

“Understanding whether the opioid system is involved ketamine’s antidepressant effects is a really important question, given how much we still don't know about how ketamine works. “Our study shows that the opioid system is involved and offers insight into how it contributes to ketamine’s effects.”

022 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 09/06/2025

Spoke with @peerj.bsky.social‬ about my research after receiving 1st Prize for Best Poster at the Winter Conference on Brain Research 2025. #WCBR2025 peerj.com/blog/post/11... Grateful for the chance to share what drives my work in interventional psychiatry.

141 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 22/05/2025

Thrilled to share that our book chapter has just been published as part of #Bipolar Disorder: An Evidence-Based Clinical Guide (Springer Nature, 2025).

230 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 07/05/2025

This recognition not only supports early-career researchers like myself, but also strengthens our collective mission to advance evidence-based care for depression and suicidality. #ADAA2025

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 07/05/2025

I’m deeply grateful to the Anxiety and Depression Association of America (@adaaanxiety.bsky.social) for honoring me with the Alies Muskin Career Development Leadership Award this year. #ADAA2025

120 0

Reposted by Igor D. Bandeira, MD, PhD

Suicide Research Symposium @suicideresearchsym.bsky.social · 21/04/2025

The fourth annual Suicide Research Symposium (#SRS25) takes place THIS WEEK, Wednesday (April 23) through Friday (April 25)! Registration is still open for our free, virtual event. Links to register and see the conference platform are on our website: www.suicideresearchsymposium.com

suicideresearchsymposium.com

SRS 2025

We are delighted to announce that the fourth annual Suicide Research Symposium will be taking place April 23-25, 2025. Like previous years, this Symposium will be free and take place virtually. We ...

12317 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/03/2025

I will present preliminary data from our randomized clinical trial (clinicaltrials.gov/study/NCT041...), examining the impact of chronic pain on #ketamine response in treatment-resistant #depression. I look forward to sharing our findings! #suicideprevention

clinicaltrials.gov

ClinicalTrials.gov

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/03/2025

Happy to share that I have been selected for the Alies Muskin Career Development Leadership Award from the Anxiety and Depression Association of America (@adaaanxiety.bsky.social)! #ADAA2025

130 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 06/03/2025

A heartfelt thank you to my collaborators, mentors, research team, and the patients who made this work possible!

000 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 06/03/2025

Our trial is investigating the efficacy and safety of buprenorphine in prolonging the antisuicidal and antidepressant effects of ketamine (clinicaltrials.gov/study/NCT041...), and the final results are coming soon!

clinicaltrials.gov

ClinicalTrials.gov

100 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 06/03/2025

It was a great honor to receive the New Investigator Award and share the preliminary data from our @afspnational.bsky.social study at the 21st Annual Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. #ISCTM2025

110 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 18/02/2025

A huge thank you to my mentors, colleagues, and collaborators who have supported my journey. I look forward to engaging with the ISCTM community and contributing to discussions on clinical trial methodology in psychiatry!

000 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 18/02/2025

Honored to have been selected for the New Investigator Award from the International Society for CNS Clinical Trials and Methodology! This recognition aligns with my passion for advancing rigorous and innovative research methodologies to improve psychiatric care. #ISCTM #ISCTM2025

110 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 10/02/2025

First prize for Best Poster Presentation at the Winter Conference on Brain Research 2025! This recognition is a reminder that perseverance pays off, even in challenging times. Proud and grateful! #WCBR #WCBR2025

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 09/02/2025

The film challenges us to embrace the chaos of difficult times, using them not as reasons to retreat but as fuel to redefine our purpose. In the face of uncertainty, we have the power to turn personal suffering into growth, resilience, and meaningful change.

000 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 09/02/2025

I’m Still Here is a raw and unconventional exploration of identity, struggle, and reinvention. It reminds us that pain and adversity, rather than breaking us, can serve as catalysts for transformation.

130 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 04/02/2025

Science thrives on collaboration, and I'm pleased to have built meaningful connections and gained new perspectives that will inspire my future work.

000 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 04/02/2025

Attending the Winter Conference on Brain Research as a Travel Fellowship Awardee was an incredible opportunity to exchange ideas with peers across preclinical and clinical research. #WCBR #WCBR2025

140 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 27/01/2025

Happy to be in beautiful Tahoe as a Travel Fellowship Awardee at the Winter Conference on Brain Research! If you're curious about interventional psychiatry, the opioid properties of #ketamine, and treatment-resistant #depression, stop by my poster tomorrow (Board #31)! #WinterBrain #WCBR2025

060 0

Reposted by Igor D. Bandeira, MD, PhD

Roxana Daneshjou, MD, PhD @roxanadaneshjou.bsky.social · 25/01/2025

The NIH diversity supplement pages have all been pulled down. What is a diversity supplement and why should the public care? A diversity supplement is funding to help diversify the research workforce. You may be wondering, “so what?”. Let me explain. www.nigms.nih.gov/Pages/PageNo...

nigms.nih.gov

National Institute of General Medical Sciences

NIGMS supports basic research to understand biological processes and lay the foundation for advances in disease diagnosis, treatment, and prevention.

9494277 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 14/12/2024

It was so nice meeting you too! Muito obrigado! :)

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 14/12/2024

Feeling deeply grateful after an incredible #ACNP2024! It was an honor to connect with inspiring colleagues, foster new connections, and reunite with lifelong friends. Special thanks to the #TravelAward2024 program for the invaluable mentorship and support. @acnporg.bsky.social

2133 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 11/12/2024

Our poster T16 on #ketamine for suicidal behavior in treatment-resistant #depression is up now at #ACNP2024! Let's discuss the comparative analysis of antisuicidal and antidepressant effects!

031 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 10/12/2024

Attending the recent panel on #suicideprevention at #ACNP2024 was truly thought-provoking. The dedication, innovative research, and shared commitment underscore the urgent need to advance effective interventions for this critical public health issue. @acnporg.bsky.social

081 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 08/12/2024

Hey #ACNP2024! Grateful to return for my 2nd year, this time as a Travel Awardee! I’m a postdoc at Stanford, working on interventional psychiatry clinical trials with #BrainStimulation and #Ketamine for depression. Hope to see you at my poster (T16) on 12/10!

1161 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 05/12/2024

Honored to be part of this incredible group of travel awardees. #ACNP2024 #TravelAward2024

181 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 28/11/2024

I will present preliminary data from our American Foundation for Suicide Prevention-funded clinical trial, which explores the use of low-dose buprenorphine to extend the antisuicide and antidepressant effects of #ketamine for treatment-resistant #depression.

010 0

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 28/11/2024

I am thrilled to announce that I have been honored with a Travel Fellowship Award to attend the 2025 Winter Conference on Brain Research!

140 0